[{"orgOrder":0,"company":"Bifarma Adiluhung","sponsor":"Bifarma Adiluhung","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDONESIA","productType":"Miscellaneous","year":"2026","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Bifarma Adiluhung","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bifarma Adiluhung \/ Bifarma Adiluhung","highestDevelopmentStatusID":"9","companyTruncated":"Bifarma Adiluhung \/ Bifarma Adiluhung"}]

Find Clinical Drug Pipeline Developments & Deals by Bifarma Adiluhung

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : Hyalein (Sodium Hyaluronate) is a small molecule drug, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of osteoarthritis, knee.

                          Product Name : Hyalein

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2026

                          Lead Product(s) : Sodium Hyaluronate,UC-MSC-Derived Secretome

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Universitas Sriwijaya

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank